Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Boehringer Ingelheim is the lead sponsor of 65 current clinical trials in our USA, UK, China, India and Ireland registers. 36 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Obrixtamig, Empagliflozin and Nerandomilast. The most-studied condition is Solid Tumours.

Company profile on this site (news, sites, medicines, approvals): Boehringer Ingelheim (DE) →

ClinicalTrials.gov trials by status

Recruiting3655%
Not yet open35%
Active, closed2640%

Trials by phase

Phase 32234%
Phase 12234%
Phase 21523%
Phase 1/246%
Observational23%

Clinical trials sponsored by Boehringer Ingelheim

65 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy NCT07472517 · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) Drugs: Atezolizumab, Carboplatin, Etoposide	Phase 3	Recruiting	2026-04	Ireland, UK, USA, China
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread NCT06324357 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Drugs: Capecitabine, MFOLFOX6, Trastuzumab	Phase 1/2	Recruiting	2024-06	UK, USA, China
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease NCT07355296 · Proteinuric Kidney Diseases Drug: Apecotrep	Phase 2	Recruiting	2026-03	UK, USA, India, China
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease NCT07064473 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases Drugs: Empagliflozin, Vicadrostat	Phase 3	Recruiting	2025-07	Ireland, UK, USA, India, China
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) NCT05471856 · Solid Tumors Drug: Ezabenlimab	Phase 1	Recruiting	2023-02	UK, USA
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis NCT06632457 · Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Recruiting	2024-11	UK, USA, India, China
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) NCT07366034 · Fibrosing Interstitial Lung Disease Drug: Nerandomilast	Phase 3	Recruiting	2026-07	UK, USA, China
A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) NCT07744152 · Solid Tumours	Phase 1	Recruiting	2026-09	China
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure NCT06424288 · ClinicalTrials.gov ↗ · Heart Failure Drugs: Empagliflozin, Vicadrostat	Phase 3	Recruiting	2024-06	UK, USA, India, China
A Study of BI 3810944 in Patients With Advanced Cancer NCT07224425 · Solid Tumours, Melanoma	Phase 1	Recruiting	2026-02	USA
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar NCT07754461 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drug: Survodutide	Phase 3	Recruiting	2026-08	USA, India
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis NCT06872892 · ClinicalTrials.gov ↗ · Bronchiectasis Drug: BI 1291583	Phase 3	Recruiting	2025-06	Ireland, UK, USA, India, China
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well NCT07361302 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke Drug: Tenecteplase	Phase 3	Recruiting	2026-02	India, China
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) NCT07409181 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus Drug: BI 3000202	Phase 2	Recruiting	2026-04	UK, USA, India, China
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations NCT06581432 · Solid Tumours Drug: Zongertinib	Phase 2	Recruiting	2024-10	UK, USA, China
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart NCT06935370 · ClinicalTrials.gov ↗ · Heart Failure Drugs: Empagliflozin, Vicadrostat	Phase 3	Recruiting	2025-05	UK, USA, India, China
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) NCT07220083 · ClinicalTrials.gov ↗ · Focal Segmental Glomerulosclerosis Drug: Apecotrep	Phase 3	Recruiting	2026-02	UK, USA, India, China
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis NCT06632444 · ClinicalTrials.gov ↗ · Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis	Phase 3	Recruiting	2024-10	UK, USA, India, China
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression NCT07540988 · ClinicalTrials.gov ↗ · Interstitial Lung Diseases Drug: Nerandomilast	Phase 3	Recruiting	2026-09	UK, USA, China
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis NCT07497087 · ClinicalTrials.gov ↗ · Systemic Sclerosis	Phase 3	Recruiting	2026-07	UK, USA, India, China
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers NCT05882058 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma	Phase 2	Recruiting	2023-10	UK, USA, China
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654 · ClinicalTrials.gov ↗ · Extrapulmonary Neuroendocrine Cancer (epNEC) Drugs: Carboplatin, Etoposide, Obrixtamig	Phase 3	Recruiting	2026-07	UK, USA, China
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases NCT06806592 · ClinicalTrials.gov ↗ · Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases Drug: Nerandomilast	Phase 3	Recruiting	2025-09	UK, USA, China
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) NCT07306559 · Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer	Phase 1	Recruiting	2026-02	USA
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 NCT05916313 · Glioma Drug: Obrixtamig	Phase 1	Recruiting	2024-01	USA
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems NCT07023354 · Healthy, Hepatic Impairment Drug: BI 1291583	Phase 1	Recruiting	2025-07	USA
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis NCT06636656 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Phase 2	Recruiting	2024-12	USA
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema NCT06962839 · ClinicalTrials.gov ↗ · Macular Edema	Phase 2	Recruiting	2025-06	UK, USA, China
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Atezolizumab, Durvalumab, Nivolumab	Phase 3	Recruiting	2026-01	UK, USA, China
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab NCT07486817 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 2	Recruiting	2026-06	China
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) NCT07107945 · ClinicalTrials.gov ↗ · Chronic Kidney Disease Drugs: Empagliflozin, Jardiance	Phase 3	Recruiting	2025-12	UK, USA
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis NCT07201922 · ClinicalTrials.gov ↗ · Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases Drug: Nerandomilast	Phase 3	Recruiting	2026-02	UK, USA
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab NCT07607678 · ClinicalTrials.gov ↗ · Advanced Solid Cancer, Metastatic Solid Cancer Drug: Ezabenlimab	Phase 1	Recruiting	2026-05	USA
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated NCT07553429 · ClinicalTrials.gov ↗ · Diabetic Macular Edema	Phase 1/2	Recruiting	2026-05	USA
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) NCT07325526 · ClinicalTrials.gov ↗ · Liver Cirrhosis	Phase 2	Recruiting	2026-02	USA
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems NCT07486102 · ClinicalTrials.gov ↗ · Healthy, Hepatic Impairment Drug: BI 3000202	Phase 1	Recruiting	2026-05	USA
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers NCT07707895 · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology Drugs: Atezolizumab, Obrixtamig, ZL-1310	Phase 1/2	Not yet open	2026-09	UK, USA, China
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies NCT07789015 · ClinicalTrials.gov ↗ · Idiopathic Inflammatory Myopathies Drug: Nerandomilast	Phase 3	Not yet open	2026-11	USA, China
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction NCT07044700 · ClinicalTrials.gov ↗ · Heart Failure of Reduced Ejection Fraction (HFrEF) Drugs: Empagliflozin, Jardiance	Observational	Not yet open	2028-01	China
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis Drug: Nerandomilast	Phase 3	Active, closed	2024-05	Ireland, UK, USA, India, China
A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON) NCT06962852 · Cystic Fibrosis	Phase 1/2	Active, closed	2025-05	UK
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy NCT06321302 · Diabetic Retinopathy	Phase 2	Active, closed	2024-05	UK, USA
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) NCT04111458 · Solid Tumors, KRAS Mutation; SOS1 Drugs: BI 1701963, Trametinib	Phase 1	Active, closed	2019-11	USA
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) NCT06531824 · ClinicalTrials.gov ↗ · Kidney Disease, Chronic Drug: Empagliflozin	Phase 3	Active, closed	2024-08	UK, USA, India, China
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies NCT06878365 · ClinicalTrials.gov ↗ · Type 1 Interferonopathies	Phase 1	Active, closed	2025-07	UK, USA
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine NCT05846230 · ClinicalTrials.gov ↗ · Bronchiectasis Drug: BI 1291583	Phase 2	Active, closed	2023-09	UK, USA
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone NCT06806852 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drugs: BI 770371, Cetuximab, Pembrolizumab	Phase 1	Active, closed	2025-05	UK, USA
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation NCT04973163 · ClinicalTrials.gov ↗ · Solid Tumors, KRAS Mutation Drugs: BI 1701963, Midazolam	Phase 1	Active, closed	2021-09	UK, USA
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine NCT06619509 · ClinicalTrials.gov ↗ · Solid Tumours	Phase 2	Active, closed	2024-12	UK, USA, China
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment NCT06151574 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 3	Active, closed	2024-02	UK, USA, China
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated NCT05327946 · Solid Tumors Drugs: BI 770371, Ezabenlimab	Phase 1	Active, closed	2022-05	USA
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer NCT04958239 · ClinicalTrials.gov ↗ · Neoplasms Drugs: Ezabenlimab, Pembrolizumab	Phase 1	Active, closed	2021-10	USA, China
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body NCT07407348 · ClinicalTrials.gov ↗ · Healthy, Obesity, Overweight	Phase 1	Active, closed	2026-03	UK
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer NCT06077500 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma (SCLC) Drugs: Atezolizumab, Carboplatin, Etoposide	Phase 1	Active, closed	2024-02	USA
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy NCT05990738 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma (SCLC) Drugs: Obrixtamig, Topotecan	Phase 1	Active, closed	2024-02	UK, USA
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight NCT07662122 · ClinicalTrials.gov ↗ · Obesity, Overweight	Phase 2	Active, closed	2026-06	UK, USA, China
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) NCT04886804 · ClinicalTrials.gov ↗ · Neoplasm Metastasis, Non-Small Cell Lung Cancer Drug: Zongertinib	Phase 1	Active, closed	2021-07	UK, USA, China
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States NCT07342309 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Observational	Active, closed	2025-09	USA
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers NCT06132113 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasms	Phase 1	Active, closed	2024-01	USA
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity NCT06745284 · ClinicalTrials.gov ↗ · Obesity Drugs: Semaglutide, Survodutide	Phase 1	Active, closed	2025-03	USA
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment NCT07036523 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis	Phase 2	Active, closed	2025-11	USA
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy NCT06769048 · ClinicalTrials.gov ↗ · Geographic Atrophy	Phase 2	Active, closed	2025-01	USA
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy NCT06722157 · ClinicalTrials.gov ↗ · Macular Degeneration, Age-related, Geographic Atrophy Drug: Pegcetacoplan	Phase 2	Active, closed	2025-01	USA
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma NCT05846516 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma Drug: Ezabenlimab	Phase 1	Active, closed	2023-05	USA
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 NCT04429087 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 Drug: Obrixtamig	Phase 1	Active, closed	2020-07	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Boehringer Ingelheim trials

35 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Boehringer Ingelheim trials

72 conditions

Solid Tumours4Interstitial Lung Diseases3Healthy3 Obesity3 Idiopathic Pulmonary Fibrosis2 Bronchiectasis2 Metastatic Breast Cancer2 Solid Tumors2 Heart Failure2Neuroendocrine Neoplasms2Lung Cancer, Non-squamous, Non-small Cell2Overweight2Small Cell Lung Carcinoma (SCLC)2Hepatic Impairment2 Geographic Atrophy2 Small Cell Lung Cancer (SCLC)1 Extensive-stage Small Cell Lung Cancer (ES-SCLC)1Progressive Pulmonary Fibrosis1Diabetes Mellitus, Type 21 Hypertension1 Cardiovascular Diseases1 Cystic Fibrosis1 Small Cell Lung Cancer1Large Cell Neuroendocrine Lung Carcinoma1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	59	33
Clinical trials in UK	38	23
Clinical trials in China	33	23
Clinical trials in India	14	12
Clinical trials in Ireland	4	3

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Solid Tumours

Sponsor	Trials
Orion Corporation, Orion Pharma	1

Sponsors with the most current trials registered for this condition.

Questions about Boehringer Ingelheim trials

How many clinical trials does Boehringer Ingelheim sponsor?

Boehringer Ingelheim is the lead sponsor of 65 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Boehringer Ingelheim trials recruiting?

Yes. 36 of its 65 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Boehringer Ingelheim testing?

Its current trials name 35 drugs and biologicals as interventions. The most frequent are Obrixtamig (7), Empagliflozin (6), Nerandomilast (6), Zongertinib (6) and Carboplatin (5). The number in brackets is how many of its trials name each drug.

Does Boehringer Ingelheim have clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Boehringer Ingelheim clinical trials